Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T A Kelly

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Journal of Medicinal Chemistry|November 24, 1995
Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymesJ R Proudfoot, K D Hargrave, S R Kapadia, et al.
The American Journal of Cardiology|July 22, 1998
Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor BlockadeS Ghaffari, D J Kereiakes, A M Lincoff, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 24, 1999
Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesionT A Kelly, D D Jeanfavre, D W McNeil, et al.
Journal of Medicinal Chemistry|May 10, 1996
Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptidesS J Coutts, T A Kelly, R J Snow, et al.
Journal of the American Chemical Society|June 14, 2001
Binding site elucidation of hydantoin-based antagonists of LFA-1 using multidisciplinary technologies: evidence for the allosteric inhibition of a protein--protein interactionK Last-Barney, W Davidson, M Cardozo, et al.
Circulation|April 20, 1999
Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockadeA M Lincoff, J E Tcheng, R M Califf, et al.
Journal of Medicinal Chemistry|March 14, 1997
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivityE S Lazer, C K Miao, C L Cywin, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Medicinal Chemistry|November 24, 1995
Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymesJ R Proudfoot, K D Hargrave, S R Kapadia, et al.
The American Journal of Cardiology|July 22, 1998
Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor BlockadeS Ghaffari, D J Kereiakes, A M Lincoff, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 24, 1999
Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesionT A Kelly, D D Jeanfavre, D W McNeil, et al.
Journal of Medicinal Chemistry|May 10, 1996
Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptidesS J Coutts, T A Kelly, R J Snow, et al.
Journal of the American Chemical Society|June 14, 2001
Binding site elucidation of hydantoin-based antagonists of LFA-1 using multidisciplinary technologies: evidence for the allosteric inhibition of a protein--protein interactionK Last-Barney, W Davidson, M Cardozo, et al.
Circulation|April 20, 1999
Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockadeA M Lincoff, J E Tcheng, R M Califf, et al.
Journal of Medicinal Chemistry|March 14, 1997
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivityE S Lazer, C K Miao, C L Cywin, et al.
Pageof 4